THE REVOLUTION IS NOW : Digital and AI in the Healthcare Industry

Presented by Mila and Novartis 

On October 21, gamechangers in the digital, AI and pharmaceutical spaces met virtualy for an in depth look at the disruption and innovation happening now and setting us up for a radically different approach to the future of healthcare.

Novartis Canadian Biome Official Launch

The Novartis Biome is a global network of innovation hubs aimed at strengthening the connection and interaction between Novartis and partners from across the digital ecosystem, from nimble startups and academia to the biggest players in the industry. The Canadian Biome will be located in Montreal, taking advantage of the strong local ecosystem.

What is the Novartis Biome?

Building a Global Network of Health Tech Leaders

The role of the patient in co-creating health-tech by Mayaan Ziv, Access Now founder and winner of Novartis Innovation Award

Fireside Chat - Imagine the possibilities

Imagine the possibilities: Fireside chat with Medable, Novartis San Francisco Biome Partner: Jake LaPorte and Dr. Michelle Longmire, CEO, Medable

Mila IA for Health

Mila presents a panel discussion and roundtables with leading digital and AI experts

Mila AI for Health

Panel with Shahram Ebadollahi, Head of Data science and AI at Novartis and Yoshua Bengio, Scientific Director at Mila hosted by Stéphanie Doyle, Director, Business Development, Life Sciences & Health Technologies, Foreign Investments at Montreal International

Research at the intersection of Mental Health and AI

Round table with Irina Rish, Associate Professor in the Computer Science and Operations Research Department at the Université de Montréal (UdeM) and a core faculty member of MILA – Quebec AI Institute and Guillermo Cecchi, Principal Research Staff Member, Manager, Computational Psychiatry and Neuroimaging at the Computational Biology Center

Good Paper vs Good Product: How Should We Commercialize Academic Research?

How do you commercialize your research? Why do most innovations created in academia never make it to patients? What’s the best way to build bridges to make it happen? Those are a few of the topics to be addressed in this roundtable, with innovators who have seen innovation successfully go from research to commercial product in healthcare. Round Table with Jeremi Lavoie, Co-Founder and CEO of AFX Medical and Luc Sirois, Executive Director – Prompt

COVID-19 Biobank

Access to high-quality data and samples from SARS-CoV-2 infected patients and controls is essential to better understand the determinants of COVID-19 disease susceptibility, severity and outcome. The mission of the Québec COVID-19 Biobank (BQC19, bqc19.ca) is to provide this type of data and samples to the COVID-19 research community. To that end, BQC 19 has recruited so far more than 1400 patients from the entire province, who have provided consent for the use of their data (including a detailed questionnaire and access to medical records) and samples for research and open access. Extensive analyses on their samples are ongoing, including proteomic, genomic, transcriptomic and immunologic profiling. A process is being put in place for researchers to access this unique dataset. BQC19 is co-funded by the Fonds de Recherche en Santé du Québec, Génome Québec and the Public Health Agency of Canada. Round Table with Vincent Mooser, Canada Excellence Research Chair in Genomic Medicine and Professor, Department of Human Genetics, McGill

Machine Learning in Medical Image Analysis - Towards MRI-based Precision Medicine

Round table with Tal Arbel, Professor, McGill – Canada CIFAR AI Chair, Mila, Dr Douglas Arnold, Professor McGill – Department of Neurology and Neurosurgery and Raghav Mehta, PhD Candidate, McGill who will present on Modelling and Propagating Uncertainties in Machine Learning for Medical Images of Patients with Neurological Diseases

Accepting or refusing a kidney for transplantation: building a clinical decision support tool

There are currently no reliable tools in Canada to help physicians and patients decide on the preferable strategy to accept a donor offer or refuse it and remain on waiting in anticipation to be allocated a better donor. We propose to use artificial intelligence (AI), more specifically deep-learning approaches, to develop a clinical decision support tool to help transplant physicians and candidates make an informed decision that is in the best interest of the patient when choosing to accept or refuse an organ offered by an ODO. The use of this tool could lead to increased acceptance of kidneys that have risk features for suboptimal projected long-term graft survival and increase the number of transplantations, thereby improving the health of Canadians and minimizing health-care costs. Round table with Margaux Luck, Applied Research Scientist – Mila and Dr Héloïse Cardinal, Researcher at the Center hospitalier de l’Université de Montréal (CRCHUM) Research Center and Clinical Assistant Professor, Department of Medicine at the University of Montreal.

Improving treatment efficacy and de-risking clinical trials with precision medicine

The “One size fits all” treatment approach to complex diseases is not working, as demonstrated by the high failure rate of clinical trials and low effectiveness of drugs currently on the market. The problem of patient selection is an underappreciated inflection point; mistakes are easy to make at this point but can represent the difference between a successful drug that can effectively treat a devastating disease or a failed drug program that cannot reach clinical trial endpoints. We will discuss how a precision medicine approach can help improve treatment effectiveness and reduce failure risk in clinical trials. Round table with Christian Dansereau, Ph.D., CEO & Founder – Perceiv AI

CERC in Genomic Medicine

Large-scale genomics represents a new tool to accelerate the discovery of novel therapeutics and to improve the probability of success for investigational medicines to reach the market. The McGill-based Canada Excellence Research Chair (CERC) in Genomic Medicine has as a mission to capture this opportunity. The vision is to build up a unique one-stop-shop in Québec to support the discovery and validation of new drug targets using large-scale genomics, and to perform highly informative and decisive proof-of-concept for investigational medicines in genetically selected patients. This will be done by capitalizing on recent breakthroughs in high-throughput nucleic acid sequencing, coupled with IT, AI, pharmaceutical sciences and clinical investigations, and on the unique structure of the French-Canadian and other populations in Québec. A robust strategy is being put in place, with the development of new tools and partnerships to deliver this mission. Round table with Vincent Mooser, Canada Excellence Research Chair in Genomic Medicine and Professor, Department of Human Genetics, McGill

Exploring the space of drug combinations using Active Learning

How to find two drugs whose effect is much stronger than the effect of each drug taken independently? The number of all possible drug combinations is huge, and only a tiny portion of this space has been explored so far. In order to quickly find highly synergistic combinations, we propose to iteratively query drug pairs to be tested in vitro and update our machine learning model. Round table with Paul Bertin – PhD student and Maksym Korablyov – Visiting student – Mila

AI-powered Systems Biology software for precision health and agriculture

Round Table by Sarah Jenna, co-founder and CEO of My Intelligent Machines (MIMs). As co-founder and CEO of MIMs, she translates this expertise to provide MIMs clients with cutting edge integrative genomics strategies & systems biology expert while paying particular attention to the specific needs of life scientists working in BioPharma, Agritech and research institutes.

Privacy Preserving AI Discovery Platform

Executive, clinicians, government and scientist perspective on the collaboration required to extract Real-World Evidence using distributed Real Word Data for industry collaboration. Round table with Alexandre Le Bouthillier, Co-Founder and CCO at Imagia and  Lisa Di Jorio, Director of AI Research and Strategy